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Abstract
© 2016,  Pleiades  Publishing,  Ltd.Intranasal  administration  of  the  polypeptide  APHC3,  an
antagonist of the TRPV1 receptor, had acute anxiolytic and antidepressant effects, as well as an
ability to modify the microglial response to proinflammatory stress and cytokine profile of the
hippocampus. However, the acute antidepressant effect of the polypeptide was not related to
the attenuation of  neuroiflammation and probably  had a different  mechanism. The use of
intranasal administration of the APHC3 peptide as a therapeutic approach aimed at decreasing
depression symptoms needs additional studies in order to find the mechanism of action of this
polypeptide in the central nervous system (CNS).
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